Adial Pharmaceuticals Q1 EPS $(2.19) Misses $(0.35) Estimate
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(2.19) per share which missed the analyst consensus estimate of $(0.35) by 525.71 percent. This is a 20.36 percent increase over losse
Press Release: Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update GLEN ALLEN, Va., May 15, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" o
10-Q: Quarterly report
Adial Pharmaceuticals Finalizes Separation Agreement With Dr. Johnson
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersProcessa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday's pre-market session. The company's market cap stands at $6.0 million. Cyclacel Pharmaceuticals (NASDAQ:CYCC
EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
Adial Pharmaceuticals Granted US Patent for Genetic Diagnostic, AD04 Combination to Treat Alcohol Use Disorder
Adial Pharmaceuticals (ADIL) said Monday it has been granted a US patent covering the combination of its proprietary genetic diagnostic and its lead Investigational New Drug AD04 to treat alcohol use
Adial Pharmaceuticals Granted Key Patent From the United States Patent and Trademark Office
GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'This Patent Expands Adial's Intellectual Property Protection and Covers the Combination of the Company's Proprietary Genetic Diagnostic to Identify Patients With Specific Genotypes
EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'This Patent Expands Adial's Intellectual Property Protection and Covers the Combination of the Company's Proprietary Genetic Diagnostic to Identify Pat
Adial Pharmaceuticals Announces CMO's Departure and Leadership Changes
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d
Marinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals Among Healthcare Movers
Adial Pharmaceuticals Files Prospectus Relates To Resale From Time To Time Of Up To 2.36M Shares Of Common Stock By Selling Stockholders
Adial Pharmaceuticals Files Prospectus Relates To Resale From Time To Time Of Up To 2.36M Shares Of Common Stock By Selling Stockholders
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of JPMorgan Chase & Co. (NYSE:JPM) fell sharply during Friday's session following first-quarter earnings. Net revenue (managed) of $42.5 billion (+8% Y/Y), beating the consensus of $41.8 billi
Veru, Theravance Biopharma, Adial Pharmaceuticals Among Healthcare Movers
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersPaxMedica (NASDAQ:PXMD) stock moved upwards by 104.2% to $0.84 during Friday's pre-market session. The market value of their outstanding shares is at $6.2 million. Allarity Therapeutics (NASDAQ
Top Premarket Decliners
Monogram Orthopaedics (MGRM) shares were down more than 15% in recent Friday premarket activity, paring Thursday's rally. Rallybio Corp. (RLYB) stock was 12% lower, reversing from Thursday's rally. Ad
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of NextPlat Corp (NASDAQ:NXPL) rose sharply in today's pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year NextPlat shares surged
Analysts Conflicted on These Healthcare Names: ADC Therapeutics (ADCT), Adial Pharmaceuticals (ADIL) and Steris (STE)
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Shares of Rallybio Corporation (NASDAQ:RLYB) rose sharply in today's pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individ
No Data